Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Qian Jia
- Phone Number: 028-88610620
- Email: qianjia@keymedbio.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Beijing Tongren Hospital, CMU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female subjects, aged between 18 and 75 years old (inclusive).
- Subjects who are capable of understanding the nature of the study and voluntarily signing the Informed consent form (ICF).
- Prior treatment with systemic corticosteroids (SCS) within two years before screening, and/or contraindicate to or intolerance to systemic corticosteroids, and/or with prior surgery to nasal polyps 6 months before the screening.
Exclusion Criteria:
- Allergic or intolerant to mometasone furoate spray or CM326.
- Have received allergen-specific immunotherapy that initiated within 3 months prior to randomization or planned to be initiated during the study period.
- Participated study of CM326.
- Systemic immunosuppressive therapy for inflammatory or autoimmune diseases within 8 weeks or 5 half-lives prior to baseline (whichever is longer).
- Starting leukotriene receptor antagonist therapy within 4 weeks prior to baseline.
- With antrochoanal polyps.
- With severe deviation of the nasal septum occludes at least one nostril.
- With persistent rhinitis medicamentosas.
- With acute sinusitis, nasal infection, or upper respiratory tract infection at screening.
- Have symptoms or whose CT scan suggests allergic fungal sinusitis.
- With malignant or benign neoplasm of nasal cavities.
- With other uncontrolled serious diseases or recurrent chronic diseases.
- Have severe hepatic and renal impairment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 220 mg Group
CM326 220 mg, subcutaneous (SC)
|
CM326 injection
|
|
Experimental: 440 mg Group
CM326 440 mg, subcutaneous (SC)
|
CM326 injection
|
|
Placebo Comparator: placebo
matched placebo, subcutaneous (SC)
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes from baseline of nasal polyp score (NPS) in eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP) at week 24.
Time Frame: Up to week 24
|
Up to week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Luo Zhang, Beijing Tong-Ren hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CM326-102102
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.